drugset / Trial / NCT07046117

Effect of Tezepelumab on Barrier Function in Severe Asthmatic Patients With and Without Comorbid Chronic Rhinosinusitis With Nasal Polyps

NCT07046117

Not yet recruiting 20 enrolled Medical University of Vienna
Non-randomizedSingle-groupOpen-labelBasic science

Summary

In this study, we will investigate the effect of tezepelumab on the epithelial barrier function of the upper and lower airways in patients suffering from severe asthma with and without chronic rhinosinusitis with nasal polyps. This will be achieved by analysis of epithelial barrier function upon challenge with various harmful substances (e.g. cigarette smoke extract, allergens) in cultured primary respiratory tract epithelial cells. Furthermore we will assess changes in clinical parameters, cellular composition and inflammatory mediators.

Timeline

Start
2025-10-01
Primary completion
2028-01-31
Completion
2028-08-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tezepelumab Monoclonal antibody Other